Related Experiment Video
Updated: Sep 19, 2025
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Advancements in RNA-targeted therapies for renal cell carcinoma
Hanzhong Zhang1, Anqi Lin2, Chen Cai3
1Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.
Abstract:
Renal cell carcinoma (RCC) represents a malignant neoplasm characterized by elevated mortality rates, primarily attributed to its resistance to conventional therapeutic interventions. Recent advancements in RNA-targeted therapeutic strategies, such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), aptamers, messenger RNAs (mRNAs), microRNAs (miRNAs), short hairpin RNAs (shRNAs), CRISPR/Cas9, and single-guide RNAs (sgRNAs), have shown promising efficacy in preclinical RCC models, owing to their high specificity and effectiveness. This review aims to elucidate the potential of these innovative therapeutic modalities in enhancing the efficacy of targeted therapies, overcoming drug resistance, and improving responses to immunotherapy, while also addressing their roles in RCC progression. Furthermore, the discussion emphasizes the importance of developing personalized medicine strategies to optimize patient outcomes, alongside the potential for advancing delivery mechanisms and integrating these therapeutic approaches with existing treatment modalities to maximize their efficacy.
Insights
RNA-targeted therapies show promise for treating renal cell carcinoma (RCC) by overcoming drug resistance and enhancing immunotherapy. These advanced strategies offer new hope for improving patient outcomes in this challenging cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Renal cell carcinoma (RCC) has high mortality rates due to resistance to traditional treatments.
- RNA-targeted therapies offer a novel approach to combat RCC's therapeutic challenges.
Purpose of the Study:
- To review the potential of RNA-targeted therapeutics in enhancing RCC treatment efficacy.
- To explore their role in overcoming drug resistance and improving immunotherapy responses.
- To discuss personalized medicine and advanced delivery mechanisms for RCC.
Main Methods:
- Review of preclinical data on RNA-targeted strategies including antisense oligonucleotides (ASOs), siRNAs, aptamers, mRNAs, miRNAs, shRNAs, CRISPR/Cas9, and sgRNAs.
- Analysis of their efficacy in RCC models.
- Discussion of integration with existing therapies and personalized medicine.
Main Results:
- RNA-targeted therapies demonstrate high specificity and effectiveness in preclinical RCC models.
- These modalities show potential in enhancing targeted therapy, overcoming resistance, and boosting immunotherapy.
- Their role in RCC progression and personalized treatment strategies are highlighted.
Conclusions:
- RNA-targeted therapies represent a promising frontier for improving renal cell carcinoma treatment.
- Optimizing delivery and integrating these with current treatments are key for maximizing efficacy.
- Personalized medicine approaches are crucial for enhancing patient outcomes in RCC.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:15Experimental RNAi